9 results
PrimaryTo determine the hematological response (complete response(CR) / partial response (PR)) rate as per Bladé criteria to treatment with oral LBH589 of patients with MM who have received at least two prior lines of therapy and whose disease is…
Primary:• Arm 1: To determine the maximum-tolerated dose (MTD) and doselimitingtoxicity (DLT) of single agent LBY135 and LBY135 when administered in combinationwith capecitabine to adult patients with advanced solid tumorsSecondary:• To characterize…
Primary1. To assess the hematologic response and return to chronic phase rate in patients with accelerate phase or blasts crisis whose diseae is resistant following treatment with at lest two BCR-ABL tyrosine kinase inhibitors when treated with…
1) To assess the antitumor activity of PHA-739358 administered as IV infusion according to two different dose schedules in metastatic HRPC patients progressing on standard docetaxel-based chemotherapy.2) To have a precise idea of the antitumor…
Primary objective (dose escalation arm): To determine the MTD of AUY922 as a single agent.Primary objective (phase II): At the MTD two further arms will be expanded to assess response (breast cancer)
To assess the long-term safety, tolerability and efficacy of ABT-874 in adults who have either completed or have demonstrated a loss of response (as defined in the original ABT-874 protocol) to treatment in a preceding ABT-874 study in the treatment…
To determine if PHA-739358 has an antitumor activity against breast, ovaria, pancreatic, colerectal, small and non small cell squamous lung cancer.
The aim of the present study is to investigate the effectiveness of paracetamol as intravenous subscription form versus paracetamol as rectal subscription form in order to prevent pain in neonates. To study this, therapeutic doses, the doses…
The primairy objective of the trial is to determine the efficacy of BIBW 2992 plus weekly paclitaxel compared to the investigators choise of chemotherapy alone in patients with NSCLC stage IIIb or IV progressing after experiencing a benefit from…